预约演示
更新于：2025-08-04
Nicergoline
尼麦角林
更新于：2025-08-04
概要
基本信息
原研机构- |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H26BrN3O3 |
InChIKeyYSEXMKHXIOCEJA-FVFQAYNVSA-N |
CAS号27848-84-6 |
关联
32
项与 尼麦角林 相关的临床试验CTR20241708
健康成年受试者空腹和餐后状态下单次口服尼麦角林片的随机、开放、单剂量、四周期、完全重复交叉设计的生物等效性试验
CTR20234046
健康受试者餐后状态下单次口服尼麦角林片的生物等效性试验
CTR20233222
健康成年受试者空腹和餐后状态下单次口服尼麦角林片的生物等效性试验
100 项与 尼麦角林 相关的临床结果
登录后查看更多信息
100 项与 尼麦角林 相关的转化医学
登录后查看更多信息
100 项与 尼麦角林 相关的专利（医药）
登录后查看更多信息
817
项与 尼麦角林 相关的文献（医药）2025-06-27Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Features of care of patients with cardiovascular diseases and cognitive disorders
Review
作者: Kochetkov, A.I. ; Ostroumova, O.D. ; Litvinova, S.V.
Due to the increase in life expectancy of the population, the proportion of people with cognitive impairment (CI) is also increasing. Today, it is known that cardiovascular diseases (CVD) are a significant risk factor for the development of CI. At the same time, the main substrate of CVD, including cerebrovascular events, is atherosclerosis. Statins are one of the most studied classes of drugs in the prevention of CVD. Atorvastatin (Liprimar) is one of the most studied and most frequently prescribed statins that has proven its effectiveness and safety in patients with a wide range of cardiovascular pathology. CI, in turn, lead to a decrease in functional autonomy, ability to work and adherence to treatment, thereby closing the vicious circle. Thus, therapy for CI should be initiated as early as possible, since they are a progressive disorder that eventually transforms into dementia. One of the drugs that has been used for 50 years for symptomatic therapy of CI, including dementia, chronic cerebrovascular and organic brain damage, is nicergoline (Sermion).
2025-04-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Low-frequency Raman spectroscopy as a new tool for understanding the behaviour of ionisable compounds in dispersed mesophases
Article
作者: Krog, Lasse S ; Boyd, Ben J ; Kihara, Shinji ; Mota-Santiago, Pablo ; Bērziņš, Kārlis ; Foderà, Vito
HYPOTHESIS:
Low-frequency Raman (LFR) spectroscopy is proposed as a novel non-destructive methodology to probe pH-related phase transitions in self-assembled lipid particles. In this case, dispersed lipid mesophases were composed of ionisable oleic acid (OA) or nicergoline (NG) in monoolein (MO). The sensitivity of LFR spectroscopy to low-energy intermolecular vibrations was hypothesised to be due to structural transformation in ionisable dispersed mesophases upon changes in pH.
METHOD/EXPERIMENT:
Phase transitions of dispersed mesophases of MO mixed with OA or NG were induced by varying the pH of the aqueous buffer. The structural transformations were studied using LFR spectroscopy, recording the corresponding changes in the vibrational density of states (VDOS) upon changes in pH and analysed using principal component analysis (PCA). The results were correlated with structural transitions observed in simultaneous small-angle X-ray scattering (SAXS) measurements.
FINDINGS:
The intensity of the VDOS signal of MO + OA mesophases scaled with phase-specific transformations, such as from the bi-continuous cubic Im3¯m phase (V2) or lamellar-based vesicles to the reversed hexagonal p6m phase (H2). For NG subtle changes in the lattice parameter of the V2 phase of NG + MO mesophases coincided with the apparent dissociation constant (pKaapp) of NG, however, slight variations between the pKaapp of NG determined by equilibrated samples analysed using SAXS and non-equilibrated samples analysed using LFR suggest structural hysteresis upon changes in the protonation state of NG. This approach offers an efficient method for studying the phase behaviour of lipid systems under varying pH and potentially other conditions such as temperature.
2025-01-01Therapeutic Advances in Neurological Disorders
Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
Article
作者: Xu, Lisi ; Zhang, Ruonan ; Zhang, Xiaolin ; Shang, Xiuli ; Huang, Daifa
Background::
Dementia is a serious adverse event (AE) that requires attention in clinical practice. However, information on drug-induced dementia is limited. The U.S. FDA Adverse Event Reporting System (FAERS) serves as an important resource for identifying real-world adverse drug reactions and safety signals.
Objective::
This study aimed to use FAERS data to identify drugs associated with increased dementia risk.
Design::
A secondary analysis of the FAERS database was conducted using disproportionality analysis methods.
Methods::
We reviewed dementia-related reports in the FAERS database from the first quarter of 2004 to the fourth quarter of 2023, used the Medical Dictionary for Regulatory Activity to identify dementia cases and summarized the corresponding list of potential medications, counted the dementia-causing medication classes with the highest frequency of reports, and disaggregated all medications.
Results::
The study identified 31,881 dementia-related AEs in the FAERS database, with an increasing trend over time, particularly among females and individuals over 65. Apixaban had the most reports (1631). Disproportionality analyses revealed that rivastigmine, nicergoline, aducanumab, amlodipine/atorvastatin, and dihydroergometrine had the highest risk, based on reporting odds ratio, proportional reporting ratio, and information component. Only valproate and tramadol among the top 50 drugs included a potential dementia risk in their package inserts.
Conclusion::
This study identified a list of medications associated with dementia risk, many of which lack dementia warnings on their labels. Increased monitoring is necessary for high-risk individuals, and further research is required to clarify these associations and improve patient safety.
100 项与 尼麦角林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头晕 | 中国 | 2000-12-15 | |
| 智力障碍 | 中国 | 2000-12-15 | |
| 情绪障碍 | 中国 | 1999-09-17 | |
| 外周血管疾病 | 中国 | 1999-09-17 | |
| 动脉硬化 | 韩国 | 1978-12-16 | |
| 脑梗塞 | 韩国 | 1978-12-16 | |
| 痴呆 | 韩国 | 1978-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | - | |
| 精神病性情感障碍 | 临床1期 | 中国 | 2020-04-30 | |
| 血管性痴呆 | 临床1期 | 中国 | 2020-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用